SW
XTLB

SteelPeak Wealth’s XTL Biopharmaceuticals XTLB Stock Holding History

SteelPeak Wealth’s Portfolio XTLB Stock Details XTLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,918
Closed -$47K – 483
2021
Q2 		$47K Sell
2,918
-676
-19% -$9.3K ﹤0.01% 417
2021
Q1 		$48K Buy
+3,594
New +$49.5K ﹤0.01% 369

Other funds holding XTLB

NC
Noked Capital Tel Aviv, Israel $946K AUM 17.1% 1-Year Est. Return
NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SteelPeak Wealth's XTLB Position: Q3 2021 in Review

SteelPeak Wealth sold out of XTL Biopharmaceuticals (XTLB) in Q3 2021, closing a stake of 2,918 shares — an estimated $47K sold.

SteelPeak Wealth first reported a position in XTLB in Q1 2021 and held it in 2 quarters. The position peaked at $48K in Q1 2021. 6 funds tracked by Wall St. Rank hold XTLB as of Q3 2021.

  • SteelPeak Wealth reported no remaining XTL Biopharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • SteelPeak Wealth sold 2,918 XTL Biopharmaceuticals shares in Q3 2021, an estimated $47K.
  • SteelPeak Wealth first reported a position in XTL Biopharmaceuticals in Q1 2021 and held it in 2 quarters.
  • SteelPeak Wealth's XTL Biopharmaceuticals position peaked at $48K in Q1 2021.
  • 6 funds tracked by Wall St. Rank held XTL Biopharmaceuticals as of Q3 2021.

Based on SteelPeak Wealth's 13F filing for Q3 2021, filed 15 Nov 2021.